Legal firm reminds Altimmune investors of pending class action lawsuit

Investors in Altimmune have been reminded by the law firm Faruqi & Faruqi about the ongoing class action lawsuit with a deadline for lead plaintiffs set on October 6, 2025. The lawsuit concerns allegations against Altimmune, a biopharmaceutical company, for possible violations of federal securities laws.

The class action lawsuit revolves around Altimmune’s involvement in trading on the open market and its potential misleading statements regarding clinical trials of its new drug candidate, ALT-801. The lawsuit specifically alleges that Altimmune made false and/or misleading statements and failed to disclose important information about the drug candidate’s performance in clinical trials, potentially leading investors to suffer losses.

Investors who purchased Altimmune securities between May 6, 2021, and May 18, 2025, are advised to consider their legal rights as lead plaintiff deadline draws near. The law firm Faruqi & Faruqi is encouraging investors and individuals with relevant information, particularly those who may have suffered financial losses, to participate in the class action lawsuit as lead plaintiffs.

Investors are urged to act promptly as the deadline of October 6, 2025, for lead plaintiffs in the class action lawsuit against Altimmune approaches. Potential lead plaintiffs are reminded to make informed decisions before taking any action regarding their involvement in the ongoing lawsuit.

If you are an investor who purchased Altimmune securities during the specified period and have incurred financial losses, it is essential to consider participating in the class action lawsuit with the guidance of legal professionals. Any relevant information or details regarding the case are crucial for thorough investigation and legal proceedings to achieve a fair resolution for affected investors.

Investors with a stake in Altimmune and who believe they may have grounds for participating in the class action lawsuit should act promptly and seek legal counsel to protect their rights. The law firm Faruqi & Faruqi is actively pursuing the case on behalf of investors to hold Altimmune accountable for any potential violations of federal securities laws.

The pending class action lawsuit against Altimmune underscores the importance of transparency and accountability in the biopharmaceutical industry. Investors are encouraged to stay informed and seek legal guidance to address any concerns or losses incurred as a result of potential misconduct by companies like Altimmune in the securities market.